MS-related costs increase with severity of relapses
- PDF / 185,677 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 31 Downloads / 167 Views
PharmacoEconomics & Outcomes News 868, p25 - 12 Dec 2020 MS-related costs increase with severity of relapses Multiple sclerosis (MS)-related costs and all-cause costs in patients with MS increase with the severity of relapses, according to findings of a Novartis-funded study published in Advances in Therapy. Claims data from US Truven Health Analytics MarketScan Commercial Claims and Encounters, and Medicare Supplemental and Coordination of Benefits databases, from January 2013 to March 2017, were used to investigate disease-related and all-cause costs in 8775 adults diagnosed with MS who had continuous enrolment during the 12 months prior to diagnosis and in the 12-month follow-up period after the index date. Patients were stratified as having severe relapse, mild/moderate relapse or no relapse. All-cause costs included all inpatient, outpatient and emergency room costs, and pharmacy costs paid by the patient and the payer. Only 25% of patients were receiving disease-modifying therapy. MS-related medical and pharmacy costs were higher in patients with than without a relapse ($48 700 vs $24 730; p
Data Loading...
